Prognostic Role of S100A8 in Human Solid Cancers: A Systematic Review and Validation

Huang, An; Fan, Wei; Liu, Jiacui; Huang, Ben; Cheng, Qingyuan; Wang, Ping; Duan, Yiping; Ma, Tiantian; Chen, Liangyue; Wang, Yanping; Mu, Yu

doi:10.3389/fonc.2020.564248

Cited by 9 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein levels in metastatic melanoma and prostate cancer increase [ 3 , 4 ]. S100A8 overexpression is associated with tumorigenesis and poor differentiation in these tumors [ 5 ]. Although S100A8 has been studied in various cancers, its biological function in cancer remains contradictory and poorly understood.…”

Section: Introductionmentioning

confidence: 99%

S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis

Jiang

Huang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. S100 Calcium Binding Protein A8 (S100A8) is beneficial for cancer immunotherapy. However, the processes underlying its therapeutic potential have not been completely studied. Methods. The Cancer Genome Atlas provides raw data on 33 different cancer types. GEO made available GSE67501, GSE78220, and IMvigor210. We investigated S100A8’s genetic changes, expression patterns, and survival studies. The linkages between S100A8 and TME, as well as its association with immunological processes/elements and the major histocompatibility complex, were explored to effectively understand the role of S100A8 in cancer immunotherapy. Three distinct immunotherapeutic cohorts were employed to examine the relationship between S100A8 and immunotherapeutic response. Results. S100A8 expression was high in tumor tissue. The overexpression of S100A8 is associated with poor clinical outcome in patients with overall survival. S100A8 is associated with immune cell infiltration, immunological modulators, and immunotherapeutic indicators. S100A8 overexpression is connected to immune-related pathways. However, no statistically significant connection between S100A8 and immunotherapeutic response was identified. Conclusions. S100A8 may be a reliable biomarker for tumor prognosis and a viable prospective therapeutic target for human cancer immunotherapy (e.g., GBM, KIRC, LGG, and LIHC).

show abstract

Section: Introductionmentioning

confidence: 99%

S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis

Jiang

Huang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…The two-dimensional strong cation-exchange and reversed-phase nano-scale liquid chromatography–electrospray ionization tandem mass spectrometry analysis (2D-Nano-LC–ESI–MS–MS) of bile in eight patients with benign and malignant gallbladder disease found that the S100A8 of the S100 calcium-binding protein family was elevated in bile in malignant gallbladder cancer, consistent with the trend of S100A8 in tissues [ 123 ]. Alternatively, S100A8 plays a promoting role in the metastasis of CCA and is also a prognostic biomarker for breast and bladder cancer [ 124 , 125 , 126 ]. S100A9, another member of the S100 calcium-binding protein family, is also a candidate biomarker for the diagnosis of CCA, although these studies primarily evaluated S100A9 in serum and tissues [ 127 , 128 ].…”

Section: Search For Cca Diagnosis Biomarkers In Human Bile At Protein...mentioning

confidence: 99%

Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study

Bao

Liu

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a multifactorial malignant tumor of the biliary tract, and the incidence of CCA is increasing in recent years. At present, the diagnosis of CCA mainly depends on imaging and invasive examination, with limited specificity and sensitivity and late detection. The early diagnosis of CCA always faces the dilemma of lacking specific diagnostic biomarkers. Non-invasive methods to assess the degree of CAA have been developed throughout the last decades. Among the many specimens looking for CCA biomarkers, bile has gotten a lot of attention lately. This paper mainly summarizes the recent developments in the current research on the diagnostic biomarkers for CCA in human bile at the levels of the gene, protein, metabolite, extracellular vesicles and volatile organic compounds.

show abstract

“…[ 4 , 5 ] It is imperative to identify reliable prognostic biomarkers for individualized treatment strategies to improve the clinical outcomes of patients with cancer. [ 6 ]…”

Section: Introductionmentioning

confidence: 99%

“…[4,5] It is imperative to identify reliable prognostic biomarkers for individualized treatment strategies to improve the clinical outcomes of patients with cancer. [6] A-kinase interacting protein (AKIP1), also known as breast cancer-associated protein 3, was originally identified in breast and prostate cancer cell lines via mRNA screening. [7] It is an intracellular protein localized in the cytoplasm, nucleus, and mitochondria, acting as an adaptor of intracellular structural proteins.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of A-kinase interacting protein 1 expression in various cancers

Xue

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Cumulative evidence suggests that A-kinase interacting protein 1 (AKIP1) plays an important role in tumor progression. However, the prognostic value of AKIP1 expression in various cancers remains unclear. Here, we conducted a meta-analysis to evaluate the prognostic value of AKIP1 expression in patients with cancer. Methods: The PubMed, Web of Science, EMBASE, CNKI, and Wanfang databases were systematically searched to identify studies in which the effect of AKIP1 expression on prognosis (overall survival or disease-free survival) was investigated. Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to assess the effect of AKIP1 expression on patient survival. Odds ratios (ORs) with 95% CIs were pooled to estimate the association between AKIP1 expression and clinicopathological characteristics of patients with cancer. Results: Nineteen eligible studies, encompassing 3979 patients, were included in the meta-analysis. AKIP1 expression was negatively associated with overall survival (HR = 1.86, 95% CI: 1.58–2.18, P < .001) and disease-free survival (HR = 1.69, 95% CI: 1.53–1.87, P < .001) in patients with cancer. Moreover, AKIP1 overexpression was positively correlated with adverse clinicopathological features, such as tumor size (OR = 2.22, 95% CI: 1.67–2.94, P < .001), clinical stage (OR = 2.05, 95% CI: 1.45–2.90, P < .001), depth of tumor invasion (OR = 2.98, 95% CI: 2.21–4.02, P < .001), and degree of lymph node metastasis (OR = 2.12, 95% CI: 1.75–2.57, P < .001). Conclusions: High AKIP1 expression is an unfavorable prognostic biomarker and may serve as a potential therapeutic target in patients with cancer.

show abstract

Prognostic Role of S100A8 in Human Solid Cancers: A Systematic Review and Validation

Cited by 9 publications

References 44 publications

S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis

S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis

Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study

Prognostic significance of A-kinase interacting protein 1 expression in various cancers

Contact Info

Product

Resources

About